Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential

Therapeutic Advances in Musculoskeletal Disease

Volumn 9, Issue 2, 2017, Pages 37-44

  Kuriya, Bindee ^a   Cohen, Marc D ^b   Keystone, Ed ^c  

^a University of Toronto   (Canada)

^b MAYO CLINIC   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

baricitinib; Janus kinase inhibitors; rheumatoid arthritis

Indexed keywords

BARICITINIB; JANUS KINASE 2 INHIBITOR; JANUS KINASE 3 INHIBITOR; TOFACITINIB;

DRUG HYPERSENSITIVITY; DRUG SAFETY; HERPES ZOSTER; HUMAN; IMMUNOREACTIVITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 85012119067     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X16687481     Document Type: Review

References (18)

1. **O’Shea J., Holland S., Staudt L., JAKs and STATs in immunity, immunodeficiency, and cancer. N Eng J Med 368: 161–170. This is a clear and concise review of this complicated subject.
2. Tanaka Y., Yamaoka K., JAK inhibitor for treating rheumatoid arthritis: from basic to clinical. Mod Rheumatol 23: 415–424.
3. **Scott L., Tofacitinib: a review of its use in adult patients with rheumatoid arthritis. Drugs 73: 857–874. This is an inclusive review which includes preclinical observations and presentation of the important aspects of the tofacitinib clinical trials.
4. U.S. Food and Drug Administration. FDA approves Xeljanz for rheumatoid arthritis, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327152.htm (accessed 11 October 2016).
5. Eli Lilly and Company. Lily and Incyte announce submission of new drug application to FDA for oral once-daily baricitinib for treatment of moderate-to-severe rheumatoid arthritis, https://investor.lilly.com/releasedetail.cfm?ReleaseID=950678 (accessed 15 October 2016).
6. Fridman J., Scherle P., Collins R.. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184: 5298–5307.
7. Shi J., Chen X., Lee F.. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK1/2 inhibitor, in healthy volunteers. J Clin Pharmacol 2014; 54: 1354–1361.
8. Greenwald M., Fidelus-Gort R., Levy R.. A randomized dose-ranging, placebo-controlled study of INCN028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis. Arthritis Rheum 62(Suppl. 10): 2172.
9. Keystone E., Taylor P., Drescher E.. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 74: 333–340.
10. Dougados M., van der Heijde D., Chen Y.. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. Epub ahead of print, 2 November 2016.
11. Emery P., Gaich C., DeLozier A.. Patient-reported outcomes from a phase III study of baricitinib in patients with rheumatoid arthritis with inadequate –response to conventional synthetic disease-modifying antirheumatic drugs. Ann Rheum Dis. Epub ahead of print, 31 October 2016.
12. Genovese M., Kremer J., Zamani O.. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374: 1243–1252.
13. Kremer J., Dougados M., Genovese M.. Response to baricitinib at 4 weeks predicts response at 12 and 24 weeks in patients with rheumatoid arthritis: results from two phase 3 studies. Arthritis Rheumatol 67(Suppl. 10): 1368–1370.
14. Fleischmann R., Schiff M., van der Heijde D.. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. Epub ahead of print, 9 October 2016.
15. Taylor P., Keystone E., van der Heijde D.. Baricitinib versus placebo or adalimumab in patients with active rheumatoid arthritis and an inadequate response to background methotrexate therapy: results of a phase 3 study. Arthritis Rheumatol 67(Suppl. 10): 3927–3931.
16. Takeuchi T., Genovese M., Xie L.. Baricitinib dose stepdown following disease control in patients with rheumatoid arthritis. Ann Rheum Dis 75(Suppl. 2): 144.
17. Smolen J., Genovese M., Takeuchi T.. Safety profile of baricitinib in patients with active RA: an integrated analysis. Ann Rheum Dis 75(Suppl. 2): 243–244.
18. Genovese M., Keystone E., Taylor P.. 24-week results of a blinded phase 2b dose-ranging study of baricitinib, an oral janus kinase 1/januse kinase 2 inhibitor, in combination with traditional disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum 64 (Suppl. 10): S1049–S1050.